T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Supercharged immune cells take on hard-to-treat blood cancers
Disease control Recruiting nowThis study tests whether giving specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, is safe and effective for people with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and multiple myeloma. About 80 participants will…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:57 UTC
-
New hope for tough blood cancers: drug combo trial opens
Disease control Recruiting nowThis study is for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma that has come back or not responded to treatment. Researchers are adding a new drug, capivasertib, to a standard chemotherapy and venetoclax regimen to see if it is safe and works better. T…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Engineered donor cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with T-cell leukemia or lymphoma that has come back. The treatment uses specially trained immune cells from a healthy donor, designed to recognize and attack cancer cells carrying a marker called CD7. The goal is to see if t…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Engineered immune cells take aim at hard-to-treat t-cell cancers
Disease control Recruiting nowThis early-phase trial tests a new treatment for people with T-cell leukemia or lymphoma that has come back or not responded to standard therapy. Doctors take a patient's own T cells, modify them in the lab to recognize and attack cancer cells carrying the CD7 protein, and infuse…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Promising drug cocktail targets tough blood cancers in kids
Disease control Recruiting nowThis study tests whether a combination of three drugs—calaspargase pegol-mknl, decitabine, and venetoclax—can help control relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LLy) in patients aged 1 month to 21 years. T…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
Engineered immune cells target tough blood cancers in early trial
Disease control Recruiting nowThis early-phase trial tests whether a new type of CAR T-cell therapy, made from a patient's own blood cells, is safe for children and adults with T cell leukemia or lymphoma that has come back or not responded to standard treatments. Participants receive a short course of chemot…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New hope for kids with tough leukemia: targeted drugs added to chemo
Disease control Recruiting nowThis study tests whether adding dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs alongsi…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD7 CAR T-cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to target and kill cancer cells. The …
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
New drug aimed at wiping out hidden leukemia cells after chemo
Disease control Recruiting nowThis study tests whether daratumumab can eliminate tiny amounts of leukemia that remain after chemotherapy in people with T-cell acute lymphoblastic leukemia (T-ALL). About 20 adults whose cancer has come back or not fully cleared will receive the drug. The goal is to see if it c…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Engineered cells take on tough blood cancer in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called OC-1, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack a specific marker (CD1a) on cancer cells. The trial aims to see if this therapy is safe and can help shrink or elim…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: OneChain Immunotherapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New universal CAR t therapy targets tough blood cancers
Disease control Recruiting nowThis early-phase trial tests a new type of CAR T cell therapy that can be given to any patient with certain blood cancers, like T-cell leukemia or lymphoma. The therapy targets a protein called CD7 found on cancer cells. The study will enroll 30 people to check if the treatment i…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Supercharged immune cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment for people with T-cell leukemia or lymphoma that has come back. Doctors take a patient's or donor's immune cells, add a special receptor (anti-CD5 with CD28) to help them recognize and attack cancer cells, then give them back. The main…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New immunotherapy combo aims to control aggressive T-Cell cancers in kids and young adults
Disease control Recruiting nowThis early-phase trial tests whether adding the drug daratumumab after a stem cell transplant can help control high-risk T-cell acute lymphoblastic leukemia or lymphoma in children, adolescents, and young adults. About 30 participants will receive the drug intravenously following…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New CAR-T therapy targets tough t-cell cancers in phase 2 trial
Disease control Recruiting nowThis study tests a treatment called WU-CART-007 for people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or not responded to other treatments. The therapy uses donor immune cells engineered to find and attack cancer cells. The goal is to se…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:10 UTC
-
Promising combo aims to boost remission in rare blood cancer
Disease control Recruiting nowThis study tests whether combining venetoclax with azacitidine can help people with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) achieve remission. About 28 participants aged 15 and older will receive the drug combination for up to two 21-day cycles. The main goal …
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 08, 2026 13:07 UTC